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policy would have taken effect. This could be related to the year on year
increase in the percentage of women being sexually active before the age of 16
years: 29.2% according to the latest Natsal survey (Mercer et al, 2013). It seems
to us feasible that failing to treat several thousand women with CIN3, along
with similar numbers with CIN2 (about a third of which progress to CIN3),
may have contributed to the increase in invasive cancers seen in women aged
25–29 years.
Castanon et al (2013a) cite an article of ours (Herbert et al, 2008) that
provided preliminary results of a 9-year audit of 133 cervical cancers that was
published in 2010 along with concurrent cases of CIN2þ diagnosed at Guy’s
and St Thomas’ (Herbert et al, 2010). In that audit we defined screen-detected
cancers as cases diagnosed in asymptomatic women investigated for abnormal
cytology and found that 15 (83.3%) of 18 cancers in women aged 20–29 years
were screen-detected IA or IB1 cancers. The treatment of IA cancer is
not the same as that of CIN3 as suggested by Castanon et al (2013a), and the
effect of a ‘cancer diagnosis’ on a woman as young as 25–29 years may be
devastating. During the period of our audit, only 3 of 41 IA cancers had a
single large loop excision of the transformation zone (LLETZ), compared with
85 of 100 cases of CIN3 (Table 1). The most frequent treatment of IA
cancer was LLETZ followed by knife cone biopsy, because many of these
cancers arise in widespread CIN3 that may be difficult to excise completely on
a LLETZ; 5 had trachelectomy and 15 had hysterectomies. Most women
with CIN3 had a single LLETZ; those who had further treatment
tended to be slightly older. LLETZ is less likely to cause premature rupture
of membranes than repeated or larger excisional biopsies (Castanon et al,
2013b).
Disallowing screening for women aged 20–24 years, whatever their clinical
history of sexual activity, is an experiment that is unfortunately taking place
during a period of time when there are birth cohorts at increased risk and
screening coverage is falling in younger women.7 In our opinion, the view that
screening women under age 25 years causes ‘more harm than good’ is letting
down a generation of women who are above the ages of those who will benefit
from vaccination in the future.
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Sir,
Dr Herbert et al (2014, this issue) suggest that women in England born
between 1985 and 1995 have been ‘let down’ by the National Health Service. It
is true that most would neither have been vaccinated against HPV types 16
and 18 nor have been invited to screening between age 20–24. However, we
reject the notion that they have been let down. We have estimated elsewhere
(Landy et al, 2014) that the change in policy (inviting women for screening
from age 25 instead of from age 20) will have resulted in about 2800 fewer
women per 100 000 being treated for cervical intraepithelial neoplasia and
have led to at most 23 extra cancers, of which between 3 and 9 would have
been stage 1B or worse. We have seen no new data that would lead us to
change these estimates. By way of contrast, we have also estimated that
introducing a more sensitive screening test (such as primary HPV testing) in
women aged 25–64 could prevent 168 cancers per 100 000 women (even
without changing the coverage) (Castanon et al, 2013).
We agree with Dr Herbert et al that 1A1 cancers may sometimes be
treated with a knife cone under a general anaesthetic rather than by loop
excision under a local anaesthetic, but we suggest that the audit data
they present are out of date and not representative of England today. In our
audit, 92% (887 of 965) women aged 20–29 with stage 1A cancer diagnosed
since April 2007 had a cone excision. It is difficult to believe that it is
desirable to treat over 100 women with high-grade cervical intraepithelial
neoplasia by a cone excision in order to prevent one case of 1A cervical
cancer that will also be treated by cone excision (albeit possibly a more
invasive one).
The decision to only invite women for cervical screening from age 25 is
clearly emotive, but it is not helpful to refer to it as an unfortunate experiment.
It was based on an independent committee’s unanimous view that screening
women aged 20–24 was likely to cause more harm than benefit. It was
certainly not intended to be an experiment, nor does it constitute a
particularly good natural experiment. Taking into account all subsequent
evidence, we remain convinced that the combined effect of policies announced
in October 2003 (switching from conventional cytology to liquid-based
cytology; first invitation at age 25; 3-yearly screening for women aged 25–49
instead of 5-yearly, as was the practice in some parts of England; and 5-yearly
screening from age 50 to 64) was for the overall good of women in England.
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